References
- Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020;20(7):816–22. doi:10.1016/S1473-3099(20)30160-2.
- Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78. doi:10.1016/S0140-6736(20)31604-4.
- Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–93. doi:10.1016/S0140-6736(20)32466-1.
- World Health Organization. COVID-19 vaccine tracker and landscape 2021. [accessed 2021 Aug 31st]. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369(6505):806–11. doi:10.1126/science.abc6284.
- Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8.
- Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–32. doi:10.1056/NEJMoa2026920.
- Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5(1):11. doi:10.1038/s41541-020-0159-8.
- Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al.; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920–31. doi:10.1056/NEJMoa2022483.
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93. doi:10.1038/s41586-020-2639-4.
- McDonnell WM, Askari FK. DNA vaccines. N Engl J Med. 1996;334(1):42–45. doi:10.1056/NEJM199601043340110.
- Zhu FC, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–54. doi:10.1016/S0140-6736(20)31208-3.
- Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97. doi:10.1016/S0140-6736(20)31866-3.
References
- Lytras T, Tsiodras S. Lockdowns and the COVID-19 pandemic: what is the endgame? Scand J Public Health. 2021;49(1):37–40. doi:10.1177/1403494820961293.
- Poland CM, Matthews AKS, Poland GA. Improving COVID-19 vaccine acceptance: including insights from human decision- making under conditions of uncertainty and human-centred design. Vaccine. 2021;39(11):1547–50. doi:10.1016/j.vaccine.2021.02.008.
- Haidere MF, Ratan ZA, Nowroz S, Zaman SB, Jung Y-J, Hosseinzadeh H, Cho JY. COVID-19 Vaccine: critical Questions with Complicated Answers. Biomol Ther (Seoul). 2021;29(1):1–10. doi:10.4062/biomolther.2020.178.
- World Health Organization. An ad hoc WHO technical consultation managing the COVID-19 Infodemic: call for action. [Accessed 2021 Oct]. https://www.who.int/publications/i/item/9789240010314
- World Health Assembly. Report 73rd World Health Assembly Agenda item 3. COVID-19 response. 2020 May 19. [Accessed Oct 2021]. https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R1-en.pdf
- UNICEF. Vaccine misinformation management field guide. [Accessed Oct 2021]. https://www.unicef.org/mena/media/10591/file/VACCINE+MISINFORMATION+FIELD+GUIDE_eng.pdf%20.pdf
- Scheufele DA, Krause NM. Science audiences, misinformation, and fake news. Proc Natl Acad Sci U S A. 2019;116(16):7662–69. doi:10.1073/pnas.1805871115.
- MacDonald NE; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–64. doi:10.1016/j.vaccine.2015.04.036.
- van Prooijen JW, Douglas KM. Conspiracy theories as part of history: the role of societal crisis situations. Mem Stud. 2017;10(3):323–33. doi:10.1177/1750698017701615.
- Lewandowsky S, et al. The COVID-19 vaccine communication handbook. A practical guide for improving vaccine communication and fighting misinformation 2021. [Accessed 2021 Oct]. https://ohei.med.umich.edu/sites/default/files/files/downloads/FINAL%20COVID19VaccineHandbook%204%20production.pdf
- World Health Organization. Vaccine safety net. [Accessed 2021 Oct]. https://www.vaccinesafetynet.org/andhttps://www.vaccinesafetynet.org/vsn/network
- Lewandowsky S, et al. The Debunking Handbook 2020. [Accessed 2021 Oct]. https://www.climatechangecommunication.org/wp-content/uploads/2020/10/DebunkingHandbook2020.pdf
- van der Linden S, Maibach E, Cook J, Leiserowitz A, Lewandowsky S. Inoculating against misinformation. Science. 2017;358(6367):1141–42. doi:10.1126/science.aar4533.
- Schmid P, Betsch C. Effective strategies for rebutting science denialism in public discussions. Nat Hum Behav. 2019;3(9):931–39. doi:10.1038/s41562-019-0632-4.
- van der Linden S, Roozenbeek J, Compton J. Inoculating against fake news about COVID-19. Front Psychol. 2020;11:566790. doi:10.3389/fpsyg.2020.566790.
- Social Decision-making Lab, Cambridge University UK. Get bad news online game. [accessed 2021 Oct]. https://www.getbadnews.com/#introjuniorversion/https://www.getbadnews.com/wp-content/uploads/2019/03/Bad-News-Junior-info-sheet-for-educators-English.pdf
- Basol M, Roozenbeek J, Van der Linden S. Good news about bad news: gamified inoculation boosts confidence and cognitive immunity against fake news. J Cogn. 2020;3(1):2. doi:10.5334/joc.91.
- British Columbia Centre for Disease Control Kids Boost Immunity online game. [Accessed 2021 Oct]. https://kidsboostimmunity.com/
- MacDonald NE, Dubé E. Unpacking vaccine hesitancy among healthcare providers. EBioMedicine. 2015;2(8):792–93. doi:10.1016/j.ebiom.2015.06.028.
- World Health Organization. Let’s flatten the infodemic curve. [Accessed 2021 Oct]. https://www.who.int/news-room/spotlight/let-s-flatten-the-infodemic-curve
References
- World Health Organization. Vaccination and trust: how concerns arise and the role of communication in mitigating crises. 2017. [ accessed 2021 Nov]. https://www.euro.who.int/__data/assets/pdf_file/0004/329647/Vaccines-and-trust.PDF
- MacDonald NE. 2021. Bites, snacks and lunch communications for COVID-19 and COVID vaccines. Hum Vaccin Immunother. ( submitted).
- Inc Magazine. The Bite, the Snack and the Meal. 2001. [ accessed 2021 Nov]. https://www.inc.com/articles/2001/06/23143.html
- Consultant Journal. Bite, snack and meal- original reference. [ accessed 2021 Nov]. https://consultantjournal.com/blog/bite-snack-and-meal-original-reference
- MacDonald NE, Law BJ. Canada’s eight-component vaccine safety system: a primer for health care workers. Paediatr Child Health. 2017;22(4):e13–e16. doi:10.1093/pch/pxx073.
References
- Baker DP, Day R, Salas E. Teamwork as an essential component of high-reliability organizations. Health Serv Res. 2006;41(4 Pt 2):1576–98. doi:10.1111/j.1475-6773.2006.00566.x.
- Timmons S, East L. Uniforms, status and professional boundaries in hospital. Sociol Health Illn. 2011;33(7):1035–49. doi:10.1111/j.1467-9566.2011.01357.x.
- Wilde J Building cultures of transparency and openness. Implementing culture change within the NHS: contributions from Occupational Psychology. Occupational Psychology in Public Policy (OPIPP) Group Report. 2014:64–72. [accessed 2021 Nov]. https://orca.cardiff.ac.uk/111317/1/BPS%20publication.pdf
References
- Royal College of Nursing. Immunisation. [accessed 2021 Sep]. https://www.rcn.org.uk/clinical-topics/public-health/immunisation
- Royal College of Nursing. Managing childhood immunisation clinics. 2021 [accessed 2021 Sep].https://www.rcn.org.uk/professional-development/publications/managing-childhood-immunisation-clinics-uk-pub-009-860
- Royal College of Nursing. Practical and clinical guidance for vaccine administration. 2021 [accessed 2021 Sep]. https://www.rcn.org.uk/clinical-topics/public-health/immunisation/practical-and-clinical-guidance-for-vaccine-administration
- Public Health England The Green Book. [accessed 2021 Sep]. https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book
- Nursing and Midwifery Council. The code. [Accessed 2021 Sep]. https://www.nmc.org.uk/standards/code/
- Royal College of Nursing. Immunisation services and large-scale vaccination delivery during COVID-19. 2021 [accessed 2021 Sep]. https://www.rcn.org.uk/clinical-topics/public-health/immunisation/immunisation-services-and-large-scale-vaccination-delivery-during-covid-19
- Royal College of Nursing. Winter wellbeing for 2021. [accessed 2021 Sep]. https://www.rcn.org.uk/get-involved/campaign-with-us/winter-wellbeing
- Nursing and Midwifery Council. NMC caring with confidence: the code in action. [accessed 2021 Sep]. https://www.nmc.org.uk/standards/code/
- Public Health England. Immunisation training standards for healthcare practitioners 2018. [accessed 2021 Sep]. https://www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners
- Public Health England. Immunisation training of healthcare support workers: national minimum standards and core curriculum 2015. [accessed 2021 Sep]. https://www.gov.uk/government/publications/immunisation-training-of-healthcare-support-workers-national-minimum-standards-and-core-curriculum
- Royal College of Nursing. Immunisation knowledge and skills competence assessment tool 2018. [accessed 2021 Sep]. https://www.rcn.org.uk/professional-development/publications/pdf-006943
- Royal College of Nursing. Accountability and delegation. [accessed 2021 Sep]. https://www.rcn.org.uk/professional-development/accountability-and-delegation
- Human Medicines Regulations. 2012. [accessed 2021 Sep]. https://www.legislation.gov.uk/uksi/2012/1916/contents/made
- Royal College of Nursing. Medicines management. [accessed 2021 Sep]. https://www.rcn.org.uk/clinical-topics/medicines-management
References
- van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67. doi:10.1016/j.vaccine.2008.12.024.
- Gilden DH, Dueland AN, Cohrs R, Martin JR, Kleinschmidt-DeMasters BK, Mahalingam R. Preherpetic neuralgia. Neurology. 1991;41(8):1215–18. doi:10.1212/WNL.41.8.1215.
- Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84. doi:10.1056/NEJMoa051016.
- Public Health England. Herpes zoster (shingles) immunisation programme 2017 to 2018: evaluation report. [Accessed 2021 Nov]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/758888/hpr4218_shngls_vc.pdf
- Public Health England. Knowsley Local Authority Health Profile. [accessed 2021 Nov]. https://psnc.org.uk/halton-st-helens-and-knowsley-lpc/wp-content/uploads/sites/45/2018/12/Knowsley-Health-Profile-2018.pdf
References
- Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–9. doi:10.1016/j.vaccine.2009.04.067.
- Holst J, Oster P, Arnold R, Tatley M, Næss L, Aaberge I, Galloway Y, McNicholas A, O’Hallahan J, Rosenqvist E, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9(6):1241–53. doi:10.4161/hv.24129.
- Masignani V, Pizza M, Moxon ER. The development of a vaccine against meningococcus B using reverse vaccinology. Front Immunol. 2019;10:751. doi:10.3389/fimmu.2019.00751.
- Ladhani SN, Ramsay M, Borrow R, Riordan A, Watson JM, Pollard AJ. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91–95. doi:10.1136/archdischild-2015-308928.
- Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020 Aug;105(8):784–90. doi:10.1136/archdischild-2019-318047.
- Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME, et al. Vaccination of infants with meningococcal Group B vaccine (4CMenB) in England. N Engl J Med. 2020 Jan;382(4):309–17. doi:10.1056/NEJMoa1901229.
- Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B. Field evaluation of vaccine efficacy. Bull World Health Organ. 1985;63:1055–68.
- De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N. Impact of an immunization campaign to control an increased incidence of serogroup B meningococcal disease in one region of Quebec, Canada. Clin Infect Dis. 2017;64(9):1263–67. doi:10.1093/cid/cix154.
- Basta NE, Mahmoud AAF, Wolfson J, Ploss A, Heller BL, Hanna S, Johnsen P, Izzo R, Grenfell BT, Findlow J, et al. Immunogenicity of a meningococcal b vaccine during a University outbreak. New Eng J Med. 2016;375(3):220–28. doi:10.1056/NEJMoa1514866.
- Grogan J, Roos K. Serogroup B meningococcus outbreaks, prevalence, and the case for standard vaccination. Curr Infect Dis Rep. 2017;19(9):30. doi:10.1007/s11908-017-0587-4.
- Rodrigues FMP, Marlow R, Simões MJ, Danon L, Ladhani S, Finn A. Association of use of a meningococcus Group B vaccine with Group B invasive meningococcal disease among children in Portugal. JAMA. 2020;324(21):2187–94. doi:10.1001/jama.2020.20449.
- Azzari C, Moriondo M, Nieddu F, Guarnieri V, Lodi L, Canessa C, Indolfi G, Giovannini M, Napoletano G, Russo F, et al. Effectiveness and impact of the 4CMenB vaccine against Group B meningococcal disease in two Italian regions using different vaccination schedules: a five-year retrospective observational study (2014-2018). Vaccines (Basel). 2020;8(3):469. doi:10.3390/vaccines8030469.
- Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, Maiden MCJ, Ladhani SN, Ramsay ME, Trotter C, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318–27. doi:10.1056/NEJMoa1900236.
- Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–50. doi:10.1016/j.vaccine.2020.09.050.
- Ladhani SN, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2020;ciaa1244.
- World Health Organization. Multi-drug resistant gonorrhoea. 2020. [accessed 17th 2020 Aug. https://www.who.int/news-room/fact-sheets/detail/multi-drug-resistant-gonorrhoea
- World Health Organization. Emergence of multi-drug resistant Neisseria gonorrhoeae – threat of global rise in untreatable sexually transmitted infections. 2012.[accessed 2021 Nov].https://www.who.int/publications/i/item/emergence-of-multi-drug-resistant-neisseria-gonorrhoeae—threat-of-global-rise-in-untreatable-sexually-transmitted-infections
- Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. doi:10.1016/S0140-6736(17)31449-6.
- 2020 STD Prevention Conference September 14–24, 2020: erratum. Sex Transm Dis. 2021 February;48(2):e34. doi:10.1097/OLQ.0000000000001346.
References
- Meningitis Research Foundation. Meningitis progress tracker. [accessed 2021 Sep]. https://www.meningitis.org/mpt
- World Health Assembly. Resolution WHA73.9. Global road map on defeating meningitis by 2030. 2020 Nov [accessed 2021 Sep]. https://apps.who.int/gb/ebwha/pdf_files/WHA73/A73_R9-en.pdf
- Meningitis Progress Tracker. 2021. [accessed 2021 Sep]. https://www.meningitis.org/mpt
- World Health Organization. Disease burden and mortality estimates. Child causes of death, 2000–2017. [accessed 2021 Sep]. https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) results. Seattle (United States): Institute for Health Metrics and Evaluation (IHME); 2018. [accessed 2021 Sep]. http://ghdx.healthdata.org/gbd-results-tool
- Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/S2214-109X(18)30247-X.
- Wright C, Blake N, Glennie L, Smith V, Bender R, Kyu H, Wunrow HY, Liu L, Yeung D, Knoll MD, et al. The global burden of meningitis in children: challenges with interpreting global health estimates. Microorganisms. 2021;9(2):377. doi:10.3390/microorganisms9020377.
- Global vaccine market model – demand module, Linksbridge SPC, last major update for 2019 MI4A meningococcal vaccine market study [accessed 2021 Sep].
- Bassat Q, Ordi J, Vila J, Ismail MR, Carrilho C, Lacerda M, Munguambe K, Odhiambo F, Lell B, Sow S, et al. Development of a post-mortem procedure to reduce the uncertainty regarding causes of death in developing countries. Lancet Glob Health. 2013;1(3):e125–6. doi:10.1016/S2214-109X(13)70037-8.
References
- Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. doi:10.1016/j.vaccine.2012.01.033.
- Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–5. doi:10.1073/pnas.1013758107.
- Lucidarme J, et al. Meningococcal serogroup A, B, C, W, X, and Y serum bactericidal antibody assays. Methods Mol Biol. 2019;1969:169–79.
- Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Křížová P, et al. Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019 Feb 8;37(7):991–1000. doi:10.1016/j.vaccine.2018.12.061.
- Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM, Maiden MCJ. Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020;59(1). doi:10.1128/JCM.02161-20.
- Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, Harrison OB, Bray JE, Jolley KA, Bratcher HB, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15(12):1420–8. doi:10.1016/S1473-3099(15)00267-4.
- Comanducci M, Bambini S, Caugant DA, Mora M, Brunelli B, Capecchi B, Ciucchi L, Rappuoli R, Pizza M. NadA diversity and carriage in Neisseria meningitidis. Infect Immun. 2004;72(7):4217–23. doi:10.1128/IAI.72.7.4217-4223.2004.
- Soeters HM, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2016May, 23(5), 867–9.
- Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: bIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124. doi:10.12688/wellcomeopenres.14826.1.